# SLC6A19

## Overview
The SLC6A19 gene encodes the solute carrier family 6 member 19 protein, commonly referred to as B0AT1, which is a sodium-dependent neutral amino acid transporter. This transmembrane protein is primarily expressed in the kidney and small intestine, where it plays a critical role in the reabsorption and absorption of neutral amino acids, respectively (Bröer2009The; Seow2004Hartnup). B0AT1's function is dependent on its interaction with other proteins, such as collectrin in the kidney and angiotensin-converting enzyme 2 (ACE2) in the intestine, which are essential for its proper localization and activity on the cell surface (Bröer2009The; Rudnick2013The). Mutations in the SLC6A19 gene are associated with Hartnup disorder, a condition characterized by defective amino acid transport, leading to a range of clinical symptoms (Kleta2004Mutations).

## Structure
The SLC6A19 protein, also known as B0AT1, is a sodium-dependent neutral amino acid transporter. It is composed of 634 amino acids and contains 12 predicted transmembrane regions, which are typical of transport proteins (Kleta2004Mutations). The protein's structure includes a series of transmembrane helices that form a pathway for substrate translocation. Specifically, helices 1 and 6 are involved in lining the substrate translocation pathway, with partial unwinding in the membrane allowing backbone residues to contact the cotransported Na+ ion (Bröer2009The).

The tertiary structure of SLC6A19 has been studied using homology models based on the bacterial leucine transporter LeuT, which provides insights into the conformational changes necessary for its function (Bröer2009The). The protein's quaternary structure involves interactions with other proteins, such as ACE2 in the intestine and collectrin in the kidney, which are necessary for its expression at the cell surface (Rudnick2013The).

Post-translational modifications, such as glycosylation, may affect the activity and stability of SLC6A19, although specific modifications are not detailed in the provided context. The protein's structure and function are crucial for its role in amino acid transport across epithelial cells.

## Function
The SLC6A19 gene encodes the B0AT1 transporter, a crucial protein for the transport of neutral amino acids in human cells. This transporter is primarily expressed in the kidney and small intestine, where it facilitates the reabsorption and absorption of neutral amino acids, respectively (Bröer2009The; Seow2004Hartnup). B0AT1 operates as a sodium-dependent transporter, meaning it requires the presence of sodium ions to function effectively, but it is chloride-independent (Seow2004Hartnup). 

In the kidney, B0AT1 is involved in the reabsorption of amino acids from the renal tubular fluid, while in the intestine, it aids in the uptake of amino acids from the intestinal lumen (Danthi2019Identification). The transporter is essential for maintaining amino acid homeostasis, as it ensures the proper balance and availability of amino acids necessary for various metabolic processes (Yadav2020Novel). 

B0AT1 requires interaction with specific proteins for its surface expression: collectrin in the kidney and angiotensin-converting enzyme 2 (ACE2) in the intestine (Bröer2009The). These interactions are vital for the stabilization and functional expression of B0AT1 on the cell surface, facilitating its transport activity (Rudnick2013The).

## Clinical Significance
Mutations in the SLC6A19 gene are primarily associated with Hartnup disorder, an autosomal recessive condition characterized by impaired transport of neutral amino acids across epithelial cells in the renal proximal tubules and intestinal mucosa. This leads to symptoms such as pellagra-like rashes, cerebellar ataxia, and psychosis (Kleta2004Mutations; Bröer2009The). The disorder is linked to various types of mutations in SLC6A19, including missense, nonsense, and splice site mutations, which result in diminished amino acid transport function (Seow2004Hartnup).

Hartnup disorder is characterized by aminoaciduria, a condition where neutral amino acids are excessively excreted in the urine due to defective reabsorption in the kidneys (Yahyaoui2019Amino). The disorder's symptoms resemble those of niacin deficiency, as tryptophan, a precursor for niacin, is poorly absorbed, leading to decreased serotonin levels and contributing to neurological symptoms (Bröer2009The; Yahyaoui2019Amino).

Alterations in the interaction of SLC6A19 with other proteins, such as collectrin and ACE2, can also lead to conditions similar to Hartnup disorder. These interactions are crucial for the proper function of the transporter in the kidney and intestine (Bröer2009The).

## Interactions
The SLC6A19 gene encodes the B0AT1 protein, a neutral amino acid transporter that interacts with several other proteins to perform its function. In the kidney, B0AT1 requires the presence of collectrin (TMEM27) for its stabilization and surface expression. Collectrin is a type I membrane protein that interacts with the SNARE complex and cytoskeletal elements, facilitating vesicular fusion with the plasma membrane. This interaction is crucial for the proper localization and function of B0AT1 in the renal brush border, and its absence can lead to symptoms similar to Hartnup disorder, such as aminoaciduria (Bröer2009The).

In the intestine, B0AT1 forms a complex with angiotensin-converting enzyme 2 (ACE2), which is essential for its function in peptide digestion and amino acid transport. This interaction is significant for the absorption of branched-chain amino acids and methionine (Javed2018Development; Bröer2009The). Mutations in B0AT1 that affect its interaction with ACE2 or collectrin can lead to Hartnup disorder, with distinct renal or intestinal manifestations (Bröer2009The). These interactions highlight the importance of B0AT1's partnerships with other proteins in maintaining amino acid homeostasis.


## References


[1. (Danthi2019Identification) Sanjay J. Danthi, Beirong Liang, Oanh Smicker, Benjamin Coupland, Jill Gregory, Estelle Gefteas, Drew Tietz, Helen Klodnitsky, Kristen Randall, Adam Belanger, and Theresa A. Kuntzweiler. Identification and characterization of inhibitors of a neutral amino acid transporter, slc6a19, using two functional cell-based assays. SLAS Discovery, 24(2):111–120, February 2019. URL: http://dx.doi.org/10.1177/2472555218794627, doi:10.1177/2472555218794627. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1177/2472555218794627)

[2. (Seow2004Hartnup) Heng F Seow, Stefan Bröer, Angelika Bröer, Charles G Bailey, Simon J Potter, Juleen A Cavanaugh, and John E J Rasko. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter slc6a19. Nature Genetics, 36(9):1003–1007, August 2004. URL: http://dx.doi.org/10.1038/ng1406, doi:10.1038/ng1406. This article has 220 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ng1406)

[3. (Javed2018Development) Kiran Javed, Qi Cheng, Adam J. Carroll, Thy T. Truong, and Stefan Bröer. Development of biomarkers for inhibition of slc6a19 (b0at1)—a potential target to treat metabolic disorders. International Journal of Molecular Sciences, 19(11):3597, November 2018. URL: http://dx.doi.org/10.3390/ijms19113597, doi:10.3390/ijms19113597. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms19113597)

[4. (Kleta2004Mutations) Robert Kleta, Elisa Romeo, Zorica Ristic, Toshihiro Ohura, Caroline Stuart, Mauricio Arcos-Burgos, Mital H Dave, Carsten A Wagner, Simone R M Camargo, Sumiko Inoue, Norio Matsuura, Amanda Helip-Wooley, Detlef Bockenhauer, Richard Warth, Isa Bernardini, Gepke Visser, Thomas Eggermann, Philip Lee, Arthit Chairoungdua, Promsuk Jutabha, Ellappan Babu, Sirinun Nilwarangkoon, Naohiko Anzai, Yoshikatsu Kanai, Francois Verrey, William A Gahl, and Akio Koizumi. Mutations in slc6a19, encoding b0at1, cause hartnup disorder. Nature Genetics, 36(9):999–1002, August 2004. URL: http://dx.doi.org/10.1038/ng1405, doi:10.1038/ng1405. This article has 257 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ng1405)

[5. (Yadav2020Novel) Aditya Yadav, Nishank Shah, Praveen Kumar Tiwari, Kiran Javed, Qi Cheng, Indrapal Singh Aidhen, and Stefan Bröer. Novel chemical scaffolds to inhibit the neutral amino acid transporter b0at1 (slc6a19), a potential target to treat metabolic diseases. Frontiers in Pharmacology, February 2020. URL: http://dx.doi.org/10.3389/fphar.2020.00140, doi:10.3389/fphar.2020.00140. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2020.00140)

[6. (Rudnick2013The) Gary Rudnick, Reinhard Krämer, Randy D. Blakely, Dennis L. Murphy, and Francois Verrey. The slc6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction. Pflügers Archiv - European Journal of Physiology, 466(1):25–42, December 2013. URL: http://dx.doi.org/10.1007/s00424-013-1410-1, doi:10.1007/s00424-013-1410-1. This article has 130 citations.](https://doi.org/10.1007/s00424-013-1410-1)

[7. (Yahyaoui2019Amino) Raquel Yahyaoui and Javier Pérez-Frías. Amino acid transport defects in human inherited metabolic disorders. International Journal of Molecular Sciences, 21(1):119, December 2019. URL: http://dx.doi.org/10.3390/ijms21010119, doi:10.3390/ijms21010119. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21010119)

[8. (Bröer2009The) Stefan Bröer. The role of the neutral amino acid transporter b0at1 (slc6a19) in hartnup disorder and protein nutrition. IUBMB Life, 61(6):591–599, May 2009. URL: http://dx.doi.org/10.1002/iub.210, doi:10.1002/iub.210. This article has 84 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/iub.210)